13 completed, 9 recruiting, 7 unknown, 2 terminated. 11 Phase 3, 11 Phase 4, 10 Phase 2, 3 Phase 1, 1 Not applicable.
Follow Dapagliflozin 10 mg: new trials by email Literature Review of Dapagliflozin 10 mg trials Research Report on Dapagliflozin 10 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease Dapagliflozin 10 mg, Matching Placebo - Polycystic Kidney, Autosomal Dominant | Phase 3 | Recruiting | University of Cologne | 420 | 2025-12-16 | 2026-07-28 |
| A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed) Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg - Diabete Mellitus | Phase 1 | Recruiting | Boryung Pharmaceutical Co., Ltd | 40 | 2025-07-05 | 2025-07-24 |
| A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting) Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg - Diabetes Mellitus | Phase 1 | Recruiting | Boryung Pharmaceutical Co., Ltd | 52 | 2025-07-03 | 2025-07-24 |
| Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease Dapagliflozin 10 mg - Chronic Kidney Disease Stage 5, CKD Stage 4 | Phase 3 | Recruiting | Ain Shams University | 60 | 2025-05-01 | 2025-05-21 |
| Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients Dapagliflozin 10 mg, Placebo - Heart Failure, Anthracycline-induced Cardiac Toxicity | Phase 2 | Recruiting | University Medical Centre Ljubljana | 100 | 2025-02-01 | 2025-11-24 |
| A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record Empagliflozin 10 MG, Dapagliflozin 10 MG - Diabetes Mellitus, Type 2, Heart Failure | Phase 4 | Recruiting | Herlev and Gentofte Hospital | 17200 | 2024-10-10 | 2026-09-18 |
| Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy Dapagliflozin 10 mg, Placebo - Breast Cancer | Phase 3 | Recruiting | University of Campinas, Brazil | 80 | 2024-01-30 | 2024-12-02 |
| The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL - Kidney Transplant Recipients | Phase 2 | Recruiting | University Health Network, Toronto | 20 | 2023-10-24 | 2026-05-01 |
| Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients Empagliflozin 10 MG, Dapagliflozin 10 MG - Heart Failure, Reduced Ejection Fraction Heart Failure | Not applicable | Completed | Damanhour University | 80 | 2022-11-01 | 2025-02-04 |
| SGLT2 Inhibition in Hemodialysis Dapagliflozin 10 MG, Placebo - Kidney Failure, Hemodialysis | Phase 2 | Completed | Medical University of Vienna | 220 | 2022-10-01 | 2026-03-03 |
| Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD Dapagliflozin 10 mg, Placebo - Chronic Kidney Diseases | Phase 2 | Recruiting | Tor Biering-Sørensen | 222 | 2022-06-08 | 2025-02-10 |
| DAPAgliflozin for Renal Protection in Heart Transplant Recipients Dapagliflozin 10 mg, Placebo - Heart Transplant Failure, Kidney Failure | Phase 3 | Active not recruiting | Oslo University Hospital | 430 | 2022-06-08 | 2026-07-01 |
| Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure Empagliflozin 10 MG, Dapagliflozin 10 MG, Placebo - Acute Decompensated Heart Failure | Phase 3 | Unknown | Medical University of Warsaw | 1364 | 2022-03-15 | 2023-03-20 |
| Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus. LIMA association, Tradjenta, Forxiga - Type2 Diabetes Mellitus | Phase 3 | Withdrawn | EMS | 2021-12-01 | 2022-07-27 | |
| Dapagliflozin After Transcatheter Aortic Valve Implantation Dapagliflozin 10 MG - Aortic Stenosis, Transcatether Aortic Valve Implantation | Phase 4 | Completed | Spanish Society of Cardiology | 1257 | 2021-01-27 | 2025-01-10 |
| Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery Dapagliflozin 10 MG, Placebos - Diabetes Mellitus, Type 2, Cardiac Surgery | Phase 4 | Unknown | Hongchang Guo | 500 | 2021-01-01 | 2021-10-07 |
| A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease AZD5718, Dapagliflozin 10 mg, Placebo - Chronic Kidney Disease | Phase 2 | Terminated | AstraZeneca | 613 | 2020-10-01 | 2024-12-20 |
| SGLT2 Inhibition in Older Obese Adults With Pre-diabetes Dapagliflozin 10 mg, Nutritional counseling - Aging | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 20 | 2020-06-25 | 2024-01-05 |
| Efficacy and Safety of Dapagliflozin in Acute Heart Failure Dapagliflozin 10 MG, Protocolized Diuretic Therapy - Heart Failure, Diabetes Mellitus, Type 2 | Phase 3 | Completed | Vanderbilt University Medical Center | 240 | 2020-04-01 | 2024-03-15 |
| Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial Dapagliflozin 10 MG, Placebo oral tablet - Heart Failure With Reduced Ejection Fraction (HFrEF), Diabete Type 2 | Phase 2 | Unknown | Damanhour University | 60 | 2020-03-01 | 2020-03-11 |
Showing 20 of 34. Sign in to see all of them.
Diabetes Mellitus, Type 2 (18) · Renal Insufficiency, Chronic (5) · Diabetes Mellitus (4) · Heart Failure (4) · Breast Neoplasms (2) · Renal Insufficiency (2) · Albuminuria (1) · Aortic Valve Stenosis (1) · Cardiomyopathies (1) · Carotid Artery Diseases (1) · Coronary Artery Disease (1) · Diabetic Nephropathies (1) · Glucose Intolerance (1) · Glucose Metabolism Disorders (1) · Heart Failure, Systolic (1)
AstraZeneca (5) · Boryung Pharmaceutical Co., Ltd (2) · Damanhour University (2) · University Health Network, Toronto (2) · University of Campinas, Brazil (2) · Ain Shams University (1) · Consano Clinical Research, LLC (1) · Dasman Diabetes Institute (1) · EMS (1) · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (1) · Herlev and Gentofte Hospital (1) · Hongchang Guo (1) · IInstituto Gallego de Medicina Vascular (1) · Medical University of Vienna (1) · Medical University of Warsaw (1)
Spain (7) · United States (7) · Canada (5) · Brazil (4) · Poland (4) · South Korea (4) · Sweden (4) · Germany (3) · Italy (3) · Japan (3) · Netherlands (3) · Taiwan (3) · Argentina (2) · Australia (2) · Austria (2)
Alvaro Hermida, MD, PhD (1) · Anna Maria Langkilde, MD (1) · Anna Solini, Prof (1) · Carolina Solis-Herrera (1) · David ZI Cherney, MD PhD FRCPC (1) · Hiddo J. L. Heerspink (1) · Itamar Raz, MD (1) · Jan Eriksson, MD (1) · Jianhua Ma (1) · JoAnn Lindenfeld, MD (1)
PMID 38770818, PMID 27009868, PMID 27408945, PMID 29693360, PMID 29888547, PMID 29898853, PMID 30415602, PMID 30882238, PMID 30882239, PMID 30992195, PMID 31196815, PMID 31384310, PMID 31474116, PMID 31843945, PMID 31983236, PMID 32501595, PMID 32795086, PMID 33611623, PMID 33653824, PMID 33851953, PMID 34129237, PMID 34233928, PMID 34389234, PMID 34427295, PMID 34693613, PMID 34805632, PMID 35015847, PMID 35510542, PMID 35857296, PMID 35997319, PMID 36649484, PMID 36857035, PMID 36878239, PMID 38017482, PMID 38569758, PMID 38837240, PMID 39928546, PMID 40162639, PMID 40840822, PMID 40952180, PMID 41062227, PMID 41147829, PMID 41311237, PMID 41347301, PMID 41888924, PMID 42013970
2019 (1), 2025 (1), P30AG044271 (1)